Revised SPC: Yescarta (axicabtagene ciloleucel) Dispersion for Infusion

SPC updated to state at least 1 dose of tocilizumab must be available for use in the event of cytokine release syndrome (previously stated 4 doses), and that treatment centres should have access to an additional dose of tocilizumab within 8 hours of each previous dose.


electronic Medicines compendium